Browsing by Author "Yayla V."

Now showing 1 - 10 of 10
  • No Thumbnail Available
    Item
    A whole genome screen for linkage in Turkish multiple sclerosis
    (Elsevier, 2003) Eraksoy M.; Kurtuncu M.; Akman-Demir G.; Kilinc M.; Gedizlioglu M.; Mirza M.; Anlar Ö.; Kutlu C.; Demirkiran M.; Idrisoglu H.A.; Compston A.; Sawcer S.; Tombul T.; Asker Ö.; Balkan S.; Seçkin D.; Aydin H.; Akman-Demir G.; Kiyat A.; Yapici Z.; Epçeliden T.; Çe P.; Goldenberg E.; Gültiken B.; Güvenç A.; Işik N.; Seleker T.; Idiman E.; Özakbaş S.; Irkeç C.; Nazlier B.; Forta H.; Seleker F.; Güner K.; Karabudak R.; Kilinç M.; Komsuoǧlu S.; Efendi H.; Mert M.; Mirza M.; Erdoǧan F.; Müngen B.; Bulut S.; Özer F.; Yayla V.; Petek-Balci B.; Saǧduyu A.; Sarica Y.; Demirkiran M.; Selçuki D.; Mavioǧlu H.; Siva A.; Altintaş A.; Saip S.; Sütlaş N.; Kuşçu Yandim D.; Tireli H.; Özalp K.; Türkoǧlu R.; Örken C.; Özmanoǧlu M.; Velioǧlu S.; Özdemir G.; Gücüyener D.; Özkan S.; Tunali G.; Turan F.; Utku U.; Turgut N.; Ümit S.; Us Ö.; Ince Günal D.; Ütkür Y.; Aluçlu U.; Yavaşoǧlu Ö.; Yücemen N.; Yücesan C.; Zadikoǧlu A.; Zorlu Y.
    Factors exerting recessive effects on susceptibility to complex traits are expected to be over-represented in communities having a higher frequency of consanguineous marriage. Multiple sclerosis, a typical complex trait, is relatively common in Turkey where cultural factors also determine a high rate of consanguineous marriage. Previous genetic studies of multiple sclerosis in Turkey have been confined to the search for associations with candidate genes. In order to exploit the special genetic features of the Turkish population, we performed a whole genome screen for linkage in 43 Turkish multiplex families employing 392 microsatellite markers. Two genomic regions where maximum lod score (MLS) values were suggestive of linkage were identified (chromosomes 13q and 18q23) along with a further 14 regions of potential linkage. Parametric analysis of these data using a recessive model, appropriate for populations with a high frequency of consanguinity, increased the LOD scores in four regions. © 2003 Elsevier B.V. All rights reserved.
  • No Thumbnail Available
    Item
    A database for screening and registering late onset Pompe disease in Turkey
    (Elsevier Ltd, 2018) Gokyigit M.C.; Ekmekci H.; Durmus H.; Karlı N.; Koseoglu E.; Aysal F.; Kotan D.; Ali A.; Koytak P.K.; Karasoy H.; Yaman A.; Sengun İ.S.; Sayin R.; Tiftikcioglu B.I.; Soysal A.; Tutkavul K.; Bayrak A.O.; Kısabay A.; Elci M.A.; Yayla V.; Yılmaz İ.A.; Ozdamar S.E.; Erdogan C.; Tasdemir N.; Serdaroglu Oflazer P.; Deymeer F.; Parman Y.; Kendirci M.; Sayan S.; Celebi L.G.; Uluç K.; Tanrıdağ T.; Yuceyar N.; Ekmekci O.; Colakoglu B.D.; Ozturk S.; Tireli H.; Selcuki D.; Neyal A.M.; Kayran Y.; Aluclu M.U.; Koyuncuoglu H.R.; Tokucoglu F.; Secil Y.; Guney F.; Gozke E.; Balaban H.; Akalın M.A.; Koc A.F.; Mulayim S.; Turgut N.
    The aim of this study was to search for the frequency of late onset Pompe disease (LOPD) among patients who had a myopathy with unknown diagnosis registered in the pre-diagnostic part of a novel registry for LOPD within a collaborative study of neurologists working throughout Turkey. Included in the study were 350 patients older than 18 years who have a myopathic syndrome without a proven diagnosis by serum creatine kinase (CK) levels, electrodiagnostic studies, and/or muscle pathology, and/or genetic tests for myopathies other than LOPD. Acid alpha glucosidase (GAA) in dried blood spot was measured in each patient at two different university laboratories. LOPD was confirmed by mutation analysis in patients with decreased GAA levels from either both or one of the laboratories. Pre-diagnostic data, recorded by 45 investigators from 32 centers on 350 patients revealed low GAA levels in a total of 21 patients; from both laboratories in 6 and from either one of the laboratories in 15. Among them, genetic testing proved LOPD in 3 of 6 patients and 1 of 15 patients with decreased GAA levels from both or one of the laboratories respectively. Registry was transferred to Turkish Neurological Association after completion of the study for possible future use and development. Our collaborative study enabled collection of a considerable amount of data on the registry in a short time. GAA levels by dried blood spot even from two different laboratories in the same patient may not prove LOPD. LOPD seemed to be rarer in Turkey than in Europe. © 2017 Elsevier B.V.
  • No Thumbnail Available
    Item
    Vestibular migraine, demographic and clinical features of 415 patients: A multicenter study
    (Elsevier B.V., 2022) Çelebisoy N.; Kısabay Ak A.; Özdemir H.N.; Gökçay F.; Durmaz G.S.; Kartı D.T.; Toydemir H.E.; Yayla V.; Çolpak Işıkay A.İ.; Erkent İ.; Özçelik P.; Akdal G.; Ataç C.; Bıçakcı Ş.; Göksu E.O.; Uyaroğlu F.G.
    Objective: To evaluate demographic and clinical features of vestibular migraine (VM) patients Methods: Four hundred fifteen patients with VM were evaluated by using a structured questionnaire in addition to clinical examination. Results: The mean age of headache and vertigo onset was 25 years and 39 years, respectively. In 12.3%, benign paroxysmal positional vertigo (BPPV) was detected during the interictal period. Ten percent had hearing loss on audiometry, in 8.7% it was one-sided low-frequency sensory-neural hearing loss below 2000 Hz and the history was typical for Meniere's disease (MD) in addition to VM. Tinnitus was present in 94.4%, aural fullness in 83.4%, nausea in 72.2% and vomiting in 30.5% of patients with VM/MD. The prevalence of these symptoms was higher in patients with VM/MD than in pure VM. Median attack severity determined by visual analog scale measured in centimeters from 0 to 10 was 8 for headache and 7 for vertigo for the whole group. Severe headache was significantly correlated with age of ≤ 43 years (OR: 6.831, 95% CI: [4.10–11.63]; p < 0.001) and severe vertigo was significantly correlated with age ≥ 41 years (OR: 7.073, 95% CI: [4.55–10.98]; p < 0.001). Motion sickness was revealed from past medical history in 51.8%. Family history of migraine was present in 72.5% and the age of onset of both migraine headaches (p = 0.008) and vertigo attacks (p = 0.004) was lower in these patients. Conclusion: Younger patients suffered more severe headache attacks whereas vertigo attack severity was higher in the elderly. BPPV and MD were commonly associated with VM and VM/MD was accompanied by aural and autonomic features more frequently than pure VM. Previous history of motion sickness was detected in more than half of the whole group. Family history of migraine was associated with younger onset of migraine headaches and vertigo attacks. © 2022 Elsevier B.V.
  • No Thumbnail Available
    Item
    Gastrostomy in Hospitalized Patients with Acute Stroke: “NöroTek” Turkey Point Prevalence Study Subgroup Analysis; [Hastanede Yatan Akut İnmeli Hastalarda Gastrostomi: “NöroTek” Türkiye Nokta Prevalans Çalışması Alt Grup Analizi]
    (Turkish Neurosurgical Society, 2022) Topçuoğlu M.A.; Özdemir A.Ö.; Aykaç Ö.; Milanoğlu A.; Gökçe M.; Bavli S.; Çabalar M.; Yayla V.; Erdoğan H.A.; Özkul A.; Güneş A.; Değirmenci B.; Aluçlu U.; Kozak H.H.; Güngör L.; Erdoğan M.; Acar Z.Ö.; Cenikli U.; Kablan Y.; Yılmaz A.; Genç H.; Nazliel B.; Çağlayan H.B.; Gencer E.S.; Ay H.; Demirbaş H.; Akdoğan Ö.; Emre U.; Yıldız Ö.K.; Bolayır A.; Demir T.; Tanrıverdi Z.; Tekan Ü.Y.; Akpınar Ç.K.; Özkan E.; İlik F.; Şirin H.; Güler A.; Önder H.; Bektaş H.; Öcek L.; Bakar M.; Ongun N.; Krespi Y.; Işıkay C.T.; Aslanbaba E.; Sorgun M.; Gürkaş E.; Karadeli H.H.; Midi İ.; İlgezdi İ.; Bilgiç A.B.; Akyol Ş.; Epçeliden M.T.; Atmaca M.M.; Kurşun O.; Keskin O.; Şirinocak P.B.; Baydemir R.; Akçakoyunlu M.; Öztürk Ş.; Özel T.; Ünal A.; Dora B.; Yürekli V.A.; Arlıer Z.; Eren A.; Yılmaz A.; Kısabay A.; Acar B.; Baştan B.; Niflioğlu B.; Güven B.; Kaya D.; Afşar N.; Yazıcı D.; Aytaç E.; Yaka E.; Toplutaş E.; Değirmenci E.; İnce F.B.; Büyükşerbetçi G.; Aydın İ.; Çetiner M.; Şen M.; Turgut N.; Kale N.; Çoban E.; Yeşilot N.; Ekizoğlu E.; Kizek Ö.; Birgili Ö.; Yevgi R.; Kunt R.; Giray S.; Akkaş S.Y.; Şenadım S.; Yoldaş T.; Asil T.; Duman T.; Atasoy T.; Çınar B.P.; Demir T.; Can U.; Ünsal Y.Ö.; Eşkut N.; Aslan Y.; Baş D.F.; Şener U.; Yılmaz Z.; Bozdoğan Z.; Alioğlu Z.; Arsava E.M.
    Objective: Nutritional status assessment, dysphagia evaluation and enteral feeding decision are important determinants of prognosis in acute neurovascular diseases. Materials and Methods: NöroTek is a point prevalence study conducted with the participation of 87 hospitals spread across all health sub regions of Turkey conducted on 10-May-2018 (World Stroke Awareness Day). A total of 972 hospitalized neurovascular patients [female: 53%, age: 69±14; acute ischemic stroke in 845; intracerebral hematoma (ICH) in 119 and post-resuscitation encephalopathy (PRE) in 8] with complete data were included in this sub-study. Results: Gastrostomy was inserted in 10.7% of the patients with ischemic stroke, 10.1% of the patients with ICH and in 50% of the patients with PRE. Independent predictors of percutaneous endoscopic gastrostomy (PEG) administration were The National Institutes of Health Stroke Scale score at admission [exp (β): 1.09 95% confidence interval (CI): 1.05-1.14, per point] in ischemic stroke; and mechanical ventilation in ischemic [exp (β): 6.18 (95% CI: 3.16-12.09)] and hemorrhagic strokes [exp (β): 26.48 (95% CI: 1.36-515.8)]. PEG was found to be a significant negative indicator of favorable (modified Rankin’s scale score 0-2) functional outcome [exp (β): 0.032 (95% CI: 0.004-0.251)] but not of in-hospital mortality [exp (β): 1.731 (95% CI: 0.785-3.829)]. Nutritional and swallowing assessments were performed in approximately two-thirds of patients. Of the nutritional assessments 69% and 76% of dysphagia assessments were completed within the first 2 days. Tube feeding was performed in 39% of the patients. In 83.5% of them, tube was inserted in the first 2 days; 28% of the patients with feeding tube had PEG later. Conclusion: The NöroTek study provided the first reliable and large-scale data on key quality metrics of nutrition practice in acute stroke in Turkey. In terms of being economical and accurate it makes sense to use the point prevalence method. © 2022 by Turkish Neurological Society.
  • No Thumbnail Available
    Item
    Can vestibular migraine development be predicted in patients with new onset migraine headaches?
    (ASEAN Neurological Association, 2022) Çelebisoy N.; Ak A.K.; Ataç C.; Özdemir H.N.; Gökçay F.; Durmaz G.S.; Kartı D.T.; Toydemir H.E.; Yayla V.; Işıkay A.İ.Ç.; Erkent İ.; Sarıtas A.S.; Özçelik P.; Akdal G.; Bıçakcı Ş.; Göksu E.O.; Uyaroğlu F.G.
    Objective: This study aims to determine the clinical features associated with the development of vestibular migraine (VM) in patients with migraine headaches. Methods: A cross-sectional, multicenter study was performed in nine tertiary neurology clinics. Patients with migraine without vestibular symptoms were classified as having migraine only (MO) and compared with patients with VM to determine any differences in clinical features, associated disorders, past medical history, and family history of migraine headaches. Moreover, we investigated the features that might predict the development of VM. Results: Two hundred forty-four patients with MO and 461 patients with VM were included. The age of onset of headache attacks was later in life for patients with VM (p<0.001). Migraine without aura (MwoA) was significantly more common than migraine with aura (MwA) in patients with VM (p=0.016). All associated features of migraine headaches were significantly more frequent in patients with MO than patients with VM (p<0.005). The same was true for all triggers, including fasting, sleep disturbances, menstruation, stress, flickering lights, and smartphones/computer games (p<0.005). A family history of migraine headaches was more common in MO patients (p=0.002). However, a previous history of motion sickness was significantly more common in patients with VM (p<0.001), as was aural fullness/tinnitus accompanying attacks (p<0.001). Logistic regression analysis indicated that aural fullness/tinnitus accompanying attacks and a previous history of motion sickness were risk factors for the development of VM. Conclusion: Patients with migraine reporting aural symptoms accompanying attacks and motion sickness in their past medical history are at increased risk of vestibular attacks fulfilling the diagnosis of VM later in life. © 2022, ASEAN Neurological Association. All rights reserved.
  • No Thumbnail Available
    Item
    Factors determining the response to treatment in patients with vestibular migraine
    (Taylor and Francis Ltd., 2022) Kısabay Ak A.; Çelebisoy N.; Özdemir H.N.; Gökçay F.; Saruhan Durmaz G.; Top Kartı D.; Ertaşoğlu Toydemir H.; Yayla V.; Çolpak  Işıkay A.İ.; Erkent İ.; Özçelik P.; Akdal G.; Ataç C.; Bıçakcı Ş.; Ozaydın-Göksu E.; Güleç Uyaroğlu F.
    Purpose: To find out clinical features associated with poor response to treatment in vestibular migraine (VM) Methods: VM patients treated with drugs recommended in migraine prophylaxis were included in this multicenter study. Migraine features including type, age of onset of headache and vertigo attacks, attack frequency, intensity, associated symptoms, triggering factors, presence of interictal dizziness/imbalance, anxiety, depression, history of motion sickness, and family history of migraine were noted. Amitriptyline, flunarizine, propranolol, topiramate and venlafaxine were chosen depending on patients’ individual requirements. Maximum dose of each drug was tried for 2 months to decide its efficacy. In the case of inefficacy, it was changed with another preventive drug of different class. If there was still no improvement, two drugs of different classes were combined. ≥ 50% reduction in attack frequency and severity in patients using one drug and a combination of two drugs was compared, with patients showing <50% reduction despite combination therapy, regarding their clinical features. Results: The results of 430 VM patients, 65 men and 365 women with a mean age of 42.2 ± 12.2 years (range: 17–74 years), were analyzed.     Conclusion: Cutaneous allodynia frequently associated with female sex, comorbid anxiety and depression and interictal dizziness/imbalance enhanced with comorbid anxiety were risk factors for reduced treatment response. Aural fullness might be the clue of impending concomitant Meniere’s disease not responding to migraine preventives. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
  • No Thumbnail Available
    Item
    Comparison of clinical features in patients with vestibular migraine and migraine
    (Springer Science and Business Media Deutschland GmbH, 2023) Çelebisoy N.; Ak A.K.; Ataç C.; Özdemir H.N.; Gökçay F.; Durmaz G.S.; Kartı D.T.; Toydemir H.E.; Yayla V.; Işıkay İ.Ç.; Erkent İ.; Sarıtaş A.Ş.; Özçelik P.; Akdal G.; Bıçakcı Ş.; Göksu E.O.; Uyaroğlu F.G.
    Vestibular migraine (VM) is accepted as the most common cause of spontaneous episodic vertigo. In most patients, vestibular symptoms follow migraine headaches that begin earlier in life. The aim of this multicenter retrospective study was to find out the differences between migraine patients without any vestibular symptoms (MwoV) and VM patients and to delineate the specific clinical features associated with VM. MwoV and VM patients were compared regarding demographic features, migraine headache years, headache attack frequency, intensity, symptoms associated with headache and vertigo attacks, presence of menopause, history of motion sickness and family history of migraine. Four-hundred and forty patients with MwoV and 408 patients with VM were included in the study. Migraine with aura was more frequent in patients with MwoV (p = 0.035). Migraine headache years was longer (p < 0.001) and headache intensity was higher in patients with VM (p = 0.020). Aural fullness/tinnitus was more common in patients with VM (p < 0.001) when all other associated symptoms were more frequent in patients with MwoV (p < 0.001) as well as attack triggers (p < 0.05). Presence of menopause and motion sickness history was reported more frequently by VM patients (p < 0.001). Logistic regression analysis indicated that longstanding history of migraine with severe headache attacks, aural fullness/tinnitus accompanying attacks, presence of menopause, previous motion sickness history were the differentiating clinical features of patients with VM. © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
  • No Thumbnail Available
    Item
    Acute Stroke Management in Türkiye: Intravenous Tissue Plasminogen Activator and Thrombectomy NöroTek: Türkiye Neurology Single Day Study; [Türkiye’de Akut İnme Yönetimi: IV tPA ve Trombektomi NöroTek: Türkiye Nöroloji Tek Gün Çalışması]
    (Turkish Neurosurgical Society, 2023) Topçuoğlu M.A.; Özdemir A.Ö.; Arsava E.M.; Güneş A.; Aykaç Ö.; Gencer E.S.; Çabalar M.; Yayla V.; Erdoğan H.A.; Erdoğan M.; Acar Z.Ö.; Giray S.; Kablan Y.; Tanrıverdi Z.; Tekan Ü.Y.; Asil T.; Akpınar Ç.K.; Yürekli V.A.; Acar B.; Şirin H.; Güler A.; Baydemir R.; Akçakoyunlu M.; Öcek L.; Çetiner M.; Nazlıel B.; Çağlayan H.B.; Ongun N.; Eren A.; Arlıer Z.; Cenikli U.; Gökçe M.; Bavli S.; Yaka E.; Özkul A.; Değirmenci B.; Aluçlu U.; Işıkay C.T.; Aslanbaba E.; Sorgun M.; Aytaç E.; Ay H.; Kunt R.; Şenadım S.; Ünsal Y.Ö.; Eşkut N.; Alioğlu Z.; Yılmaz A.; Genç H.; Yılmaz A.; Milanoğlu A.; Gürkaş E.; Değirmenci E.; Bektaş H.; İlgezdi İ.; Bilgiç A.B.; Akyol Ş.; Güngör L.; Kale N.; Çoban E.; Yeşilot N.; Ekizoğlu E.; Kizek Ö.; Kurşun O.; Yıldız Ö.K.; Bolayır A.; Kısabay A.; Baştan B.; Niflioğlu B.; Güven B.; Kaya D.; Afşar N.; Yazıcı D.; Toplutaş E.; Özkan E.; İlik F.; İnce F.B.; Büyükşerbetçi G.; Önder H.; Karadeli H.H.; Kozak H.H.; Demirbaş H.; Midi İ.; Aydın İ.; Epçeliden M.T.; Atmaca M.M.; Bakar M.; Şen M.; Turgut N.; Keskin O.; Akdoğan Ö.; Emre U.; Bilgili Ö.; Şirinocak P.B.; Yevgi R.; Akkaş S.Y.; Yoldaş T.; Duman T.; Özel T.; Ünal A.; Dora B.; Atasoy T.; Çınar B.P.; Demir T.; Demir T.; Can U.; Aslan Y.; Baş D.F.; Şener U.; Yılmaz Z.; Bozdoğan Z.; Özdemir G.; Krespi Y.; Öztürk Ş.
    Objective: To reveal the profile and practice in patients with acute stroke who received intravenous tissue plasminogen activator (IV tPA) and/or neuro-interventional therapy in Türkiye. Materials and Methods: On World Stroke Awareness Day, May 10, 2018, 1,790 patients hospitalized in 87 neurology units spread over 30 health regions were evaluated retrospectively and prospectively. Results: Intravenous tPA was administered to 12% of 859 cases of acute ischemic stroke in 45 units participating in the study. In the same period, 8.3% of the cases received neurointerventional treatment. The rate of good prognosis [modified Rankin score (mRS) 0–2] at discharge was 46% in 83 patients who received only IV tPA [age: 67 ± 12 years; National Institutes of Health Stroke Scale (NIHSS): 12 ± 6; hospital stay, 24 ± 29 days]; 35% in 51 patients who underwent thrombectomy (MT) alone (age: 64 ± 13 years; NIHSS: 14.1 ± 6.5; length of hospital stay, 33 ± 31 days), 19% in those who received combined treatment (age: 66 ± 14 years; NIHSS: 15.6 ± 5.4; length of hospital stay, 26 ± 35 days), and 56% of 695 patients who did not receive treatment for revascularization (age: 70 ± 13 years; NIHSS: 7.6 ± 7.2; length of hospital stay, 21 ± 28 days). The symptom-to-door time was 87 ± 53 minutes in the IV treatment group and 200 ± 26 minutes in the neurointerventional group. The average door-to-needle time was 66 ± 49 minutes in the IV tPA group. In the neurothrombectomy group, the door-to-groin time was 103 ± 90 minutes, and the TICI 2b-3 rate was 70.3%. In 103 patients who received IV tPA, the discharge mRS 0–2 was 41%, while the rate of mRS 0–1 was 28%. In 71 patients who underwent neurothrombectomy, the mRS 0–2 was 31% and mRS 0–1 was 18%. The door-to-groin time was approximately 30 minutes longer if IV tPA was received (125 ± 107 and 95 ± 83 minutes, respectively). Symptomatic bleeding rates were 4.8% in IV recipients, 17.6% among those who received only MT, and 15% in combined therapy. Globally, the hemorrhage rate was 6.8% in patients receiving IV tPA and 16.9% in MT. Conclusion: IV thrombolytic and neurointerventional treatment applications in acute ischemic stroke in Türkiye can provide the anticipated results. Heterogeneity has begun to be reduced in our country with the dissemination of the system indicated by the “Directive on Health Services to be Provided to Patients with Acute Stroke.”. © Copyright 2023 by the Turkish Neurological Society / Turkish Journal of Neurology published by Galenos Publishing House.
  • No Thumbnail Available
    Item
    Atrial Fibrillation Management in Acute Stroke Patients in Türkiye: Real-life Data from the NöroTek Study; [Türkiye’de İnme Hastalarında Atrial Fibrilasyonun Yönetimi: NöroTek Çalışması Gerçek Hayat Verileri]
    (Turkish Neurosurgical Society, 2023) Topçuoğlu M.A.; Arsava E.M.; Özdemir A.Ö.; Aykaç Ö.; Çetiner M.; Gencer E.S.; Güneş A.; Krespi Y.; Yaka E.; Öcek L.; Tanrıverdi Z.; Tekan Ü.Y.; Özkul A.; Özkan E.; Şirin H.; Güler A.; Kurşun O.; Kunt R.; Cenikli U.; Acar B.; Kablan Y.; Yılmaz A.; Işıkay C.T.; Aslanbaba E.; Sorgun M.; Bektaş H.; Çabalar M.; Yayla V.; Erdoğan H.A.; Gökçe M.; Bavli S.; Ongun N.; Keskin A.O.; Akdoğan Ö.; Emre U.; Yıldız Ö.K.; Bolayır A.; Akpınar Ç.K.; Karadeli H.H.; Özel T.; Ünal A.; Dora B.; Arlıer Z.; Eren A.; Milanoğlu A.; Nazliel B.; Çağlayan H.B.; Güven B.; Erdoğan M.; Acar Z.Ö.; Bakar M.; Giray S.; Şenadım S.; Asil T.; Demir T.; Ünsal Y.Ö.; Eşkut N.; Aslan Y.; Baş D.F.; Şener U.; Değirmenci B.; Aluçlu U.; Baştan B.; Niflioğlu B.; Yazıcı D.; Aytaç E.; İnce F.B.; Ay H.; Önder H.; Kozak H.H.; İlgezdi İ.; Bilgiç A.B.; Akyol Ş.; Güngör İ.L.; Atmaca M.M.; Şen M.; Yevgi R.; Akkaş S.Y.; Yoldaş T.; Atasoy H.T.; Çınar B.P.; Yılmaz A.; Genç H.; Kısabay A.; İlik F.; Demirbaş H.; Midi İ.; Şirinocak P.B.; Duman T.; Demir T.; Can U.; Yürekli V.A.; Bozdoğan Z.; Alioğlu Z.; Kaya D.; Afşar N.; Gürkaş E.; Toplutaş E.; Değirmenci E.; Büyükşerbetçi G.; Aydın İ.; Epçeliden M.T.; Turgut N.; Kale N.; Çoban E.; Yeşilot N.; Ekizoğlu E.; Kizek Ö.; Bilgili Ö.; Baydemir R.; Akçakoyunlu M.; Yılmaz Z.; Öztürk Ş.
    Objective: Atrial fibrillation (AF) is the most common directly preventable cause of ischemic stroke. There is no dependable neurology-based data on the spectrum of stroke caused by AF in Türkiye. Within the scope of NöroTek-Türkiye (TR), hospital-based data on acute stroke patients with AF were collected to contribute to the creation of acute-stroke algorithms. Materials and Methods: On May 10, 2018 (World Stroke Awareness Day), 1,790 patients hospitalized at 87 neurology units in 30 health regions were prospectively evaluated. A total of 929 patients [859 acute ischemic stroke, 70 transient ischemic attack (TIA)] from this study were included in this analysis. Results: The rate of AF in patients hospitalized for ischemic stroke/TIA was 29.8%, of which 65% were known before stroke, 5% were paroxysmal, and 30% were diagnosed after hospital admission. The proportion of patients with AF who received “effective” treatment [international normalization ratio ≥2.0 warfarin or non-vitamin K antagonist oral anticoagulants (NOACs) at a guideline dose] was 25.3%, and, either no medication or only antiplatelet was used in 42.5% of the cases. The low dose rate was 50% in 42 patients who had a stroke while taking NOACs. Anticoagulant was prescribed to the patient at discharge at a rate of 94.6%; low molecular weight or unfractionated heparin was prescribed in 28.1%, warfarin in 32.5%, and NOACs in 31%. The dose was in the low category in 22% of the cases discharged with NOACs, and half of the cases, who received NOACs at admission, were discharged with the same drug. Conclusion: NöroTekTR revealed the high but expected frequency of AF in acute stroke in Türkiye, as well as the aspects that could be improved in the management of secondary prophylaxis. AF is found in approximately one-third of hospitalized acute stroke cases in Türkiye. Effective anticoagulant therapy was not used in three-quarters of acute stroke cases with known AF. In AF, heparin, warfarin, and NOACs are planned at a similar frequency (one-third) within the scope of stroke secondary prophylaxis, and the prescribed NOAC dose is subtherapeutic in a quarter of the cases. Non-medical and medical education appears necessary to prevent stroke caused by AF. © 2023 by the Turkish Neurological Society / Turkish Journal of Neurology published by Galenos Publishing House.
  • No Thumbnail Available
    Item
    Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein
    (Galenos Publishing House, 2024) Koç S.; Şen S.; Terzi Y.; Kızılay F.; Demir S.; Aksoy D.B.; Kurtuluş F.; Bilge N.; Idilman E.; Uzunköprü C.; Güngör S.; Çilingir V.; Ethemoğlu Ö.; Boz C.; Gümüş H.; Kılıç A.K.; Kısabay A.; Bir L.S.; Turan Ö.F.; Soysal A.; Köseoğlu M.; Uzuner G.T.; Bayındır H.; Kabay S.C.; Çam M.; Yayla V.; Tan H.; Özcan A.; Taşkapıoğlu Ö.; Korkmaz M.; Tamam Y.; İnanç Y.; Efendi H.; Kotan D.; Yetkin M.F.; Bilgiç A.B.; Saçmacı H.; Demirci S.; Çelik Y.; Poyraz T.; Terzi M.
    Background: Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited. Aims: To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG. Study Design: Multicenter, retrospective, observational study. Methods: Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz Mayıs University’s Faculty of Medicine were included in the study. Results: Of the 104 patients with anti-MOG-IgG, 56.7% were women and 43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients. Conclusion: For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG. © Author(s).